RICHLAND, WASHINGTON – September 28, 2022 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents.
IEDA Board approves assistance for two Corridor startups The Iowa Economic Development Authority (IEDA) Board approved innovation funding to support two Corridor startups on March 18.
The patent awards Cellular Engineering Technologies the intellectual property to develop, manufacture and commercialize induced pluripotent stem cells that are virus-free and carry a much lower cancer risk
November 22, 2021 VIDA Diagnostics, Inc. (VIDA), based in Coralville, has unveiled a new AI-powered portal, further removing friction in respiratory clinical trials.
CORALVILLE, Iowa, Nov. 16, 2021 /PRNewswire/ -- VIDA Diagnostics, Inc. (VIDA) is further removing friction in respiratory clinical trials with the introduction of a new AI-powered portal. The cloud-based VIDA Intelligence Portal (VIP) streamlines challenges often associated with imaging in trials such as site onboarding, staff training, image data management, and data quality. Leveraging a powerful AI engine, the portal automates cumbersome and time sensitive tasks such as subject anonymization and quality control workflow processes.
– VMT-a-NET Phase 1 imaging study to be followed by Phase 1/2a therapy study for the treatment of neuroendocrine tumors being conducted at the University of Iowa – – Preclinical efficacy results demonstrated VMT-a-NET to significantly inhibit tumor growth and improve survival compared to untreated controls – – VMT-a-NET imaging study provisional results expected in Q4 2021 –
Millions of dollars in federal funding helped leverage private investment in a growing Corridor-based radiopharmaceutical company, expanding its economic impact and attracting top talent to Iowa.
License allows Cellular Engineering Technologies to develop, manufacture and commercialize next generation stem cell lines using CRISPR/Cas9 technology
Coralville, IA, July 7, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has entered into a collaborative partnership with Netherlands-based Pepscan Therapeutics B.V. (“Pepscan”), the all-in-one peptide service provider with proprietary peptide constraining technologies.
A growing number of Iowa-based companies trace their roots to federally funded University of Iowa research that helps them create jobs, generate wages, boost the local and state economy, and produce new knowledge, inventions, and services, according to a recent report by The Science Coalition (TSC).